-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Kiniksa Pharmaceuticals International, plc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2017 to Q3 2025.
- Kiniksa Pharmaceuticals International, plc Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $4.23M.
- Kiniksa Pharmaceuticals International, plc annual Deferred Income Tax Expense (Benefit) for 2024 was $8.13M.
- Kiniksa Pharmaceuticals International, plc annual Deferred Income Tax Expense (Benefit) for 2023 was -$33.8M, a 81.8% increase from 2022.
- Kiniksa Pharmaceuticals International, plc annual Deferred Income Tax Expense (Benefit) for 2022 was -$185M, a 1686418% decline from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)